Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by Royal Bank Of Canada from an “outperform” rating to an “underperform” rating in a note issued to investors on Friday, Marketbeat Ratings reports. They currently have a $21.00 price target on the stock, down from their previous price target of $37.00. Royal Bank Of Canada’s price objective would indicate a potential upside of 1.94% from the company’s current price.

A number of other brokerages have also issued reports on TEVA. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $32.27 target price on the stock. in a research report on Tuesday, July 4th. BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research report on Wednesday, July 5th. Wells Fargo & Company reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, June 27th. Cantor Fitzgerald set a $31.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research report on Thursday, June 22nd. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $33.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, June 23rd. One analyst has rated the stock with a sell rating, twenty-two have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited presently has a consensus rating of “Hold” and an average price target of $39.81.

Teva Pharmaceutical Industries Limited (TEVA) traded down 13.26% during mid-day trading on Friday, reaching $20.60. 93,317,085 shares of the company’s stock traded hands. The stock’s 50 day moving average is $32.05 and its 200-day moving average is $32.28. Teva Pharmaceutical Industries Limited has a 52 week low of $20.41 and a 52 week high of $55.45. The stock has a market capitalization of $20.93 billion, a PE ratio of 264.10 and a beta of 0.46. Teva Pharmaceutical Industries Limited also was the target of unusually large options trading activity on Thursday. Investors purchased 66,716 put options on the company. This represents an increase of 864% compared to the typical daily volume of 6,922 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.18% and a negative net margin of 25.18%. The business’s revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the business posted $1.25 earnings per share. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.65 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/06/teva-pharmaceutical-industries-limited-teva-downgraded-by-royal-bank-of-canada-to-underperform.html.

Several hedge funds have recently modified their holdings of TEVA. Greylin Investment Mangement Inc. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 36.9% in the second quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock worth $9,783,000 after buying an additional 79,300 shares during the last quarter. PGGM Investments boosted its stake in shares of Teva Pharmaceutical Industries Limited by 12.0% in the second quarter. PGGM Investments now owns 1,528,097 shares of the company’s stock worth $50,763,000 after buying an additional 163,292 shares during the last quarter. Schulhoff & Co. Inc. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 9.5% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company’s stock worth $372,000 after buying an additional 1,004 shares during the last quarter. Heritage Investors Management Corp boosted its stake in shares of Teva Pharmaceutical Industries Limited by 17.5% in the first quarter. Heritage Investors Management Corp now owns 188,990 shares of the company’s stock worth $6,065,000 after buying an additional 28,135 shares during the last quarter. Finally, Bank Hapoalim BM boosted its stake in shares of Teva Pharmaceutical Industries Limited by 9.2% in the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock worth $375,000 after buying an additional 980 shares during the last quarter. Institutional investors and hedge funds own 56.20% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.